About Monte Rosa Therapeutics
Monte Rosa Therapeutics is a publicly listed company based in Cambridge (United States) founded in 2020. Small molecule degraders are developed for cancer protein targeting. Monte Rosa Therapeutics has raised $223.5 million across 3 funding rounds from investors including Fidelity Investments, BlackRock and RTW Investments. The company has 134 employees. Its website monterosatx.com draws about 28 thousand monthly visits. Monte Rosa Therapeutics offers products and services including Molecular Glue Degraders. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Monte Rosa Therapeutics AG.
Company details
Monte Rosa Therapeutics was founded in 2020 in Cambridge, United States, within the biotechnology sector. Small molecule degraders are created to reprogram protein homeostasis pharmacologically. Targeted protein degradation is facilitated through molecular glues that control ubiquitination of disease-causing proteins by E3 ligase complexes. Operations focus on oncology therapeutics, with Thalidomide developed specifically for multiple myeloma treatment.
- Headquarters Cambridge, United States
- Employees 134
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website monterosatx.com
- Social LinkedIn X
- Legal Name Monte Rosa Therapeutics, Inc.
- Annual Revenue$123.67 M (USD)63.54as on Dec 31, 2025
- Net Profit-$38.63 M (USD)46.87as on Dec 31, 2025
- EBITDA-$45.85 M (USD)37.18as on Dec 31, 2025
- Total Equity Funding$223.5M (USD)
in 3 rounds
- Latest Funding Round$95M (USD), Series C
Mar 2021
- InvestorsFidelity Investments
& 12 more
- Employee Count134
Products & Services of Monte Rosa Therapeutics
Monte Rosa Therapeutics offers a comprehensive portfolio of products and services, including Molecular Glue Degraders.
Programs targeting undruggable diseases through innovative degraders
Funding Insights of Monte Rosa Therapeutics
Monte Rosa Therapeutics has successfully raised a total of $223.5M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $95 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $223.5M
- Total Rounds 3
- Last Round Series C — $95M
- First Round $32.5M
(May 2020)
- Investors Count 13
All 3 funding rounds of Monte Rosa Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2021 | $95M | Series C | – | Avoro Capital Advisors | |
| Sep 2020 | $96M | Series B | – | Aisling Capital | |
| May 2020 | $32.5M | Series A | – | Versant Ventures, New Enterprise Associates | – |
13 investors in total: 13 institutional.
Investors in Monte Rosa Therapeutics
Monte Rosa Therapeutics has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, BlackRock and RTW Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on biotechnology startups | avorocapital.com | New York, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Venture capital fund focused on tech startups | sixtydegreecapital.com | North York, Canada | ||
Investing in Life Sciences sectors like Healthcare and Biotechnology. | casdincapital.com | |||
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Amzak Health is engaged in venture investments in life sciences. | amzakhealth.com | New York, United States |
Investor details for Monte Rosa Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Monte Rosa Therapeutics
58 people are tracked at Monte Rosa Therapeutics (27 in leadership, 12 in board & advisors, 19 in team); the tracked headcount is 134.
| Name | Role | Group |
|---|---|---|
Markus Warmuth | CEO | Leadership |
Filip Janku | Chief Medical Officer | Leadership |
Sharon Townson | CTO | Leadership |
Reinaldo Almeida | Director | Leadership |
Jt Rynak | Head Talent Acquisition | Leadership |
Jullian G. Jones | SVP, Head of Business Development | Leadership |
Jennifer Champoux | Chief People & Operations Officer | Leadership |
Lachlan Campbell | Vice President Of Intellectual Property | Leadership |
Karin von Hodenberg | Vice President Of Quality | Leadership |
Chris Carolan | Vice President, Head Of Contracts Management, Data Privacy And Insurance & Risk Management | Leadership |
Elizabeth Hirsch | Associate Director Clinical Operations | Leadership |
Bradley Demarco | Associate Director | Leadership |
Miki Hayano | Senior Director Business Development | Leadership |
Ralph Tiedt | VP Oncology | Leadership |
Alison Paterson | Vice President | Leadership |
Pablo Gainza | Director | Leadership |
Sophia Nguyen | Director, DMPK | Leadership |
Meghan Weinreb | Director, Quality Systems | Leadership |
Ravi Krishna | Director IT Clinical System & CSV | Leadership |
Ryan Groth | Vice President - Head Of IT | Leadership |
38 more people are available in the full profile.
Complete people profiles for Monte Rosa Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Monte Rosa Therapeutics
Monte Rosa Therapeutics is a publicly listed company on the NASDAQ with ticker symbol GLUE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date24 Jun 2021
- Listed onNASDAQ: GLUE
- Listed entityMonte Rosa Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS61225M1027
- Share price$9.89 (-5.99% on the day) · 2026-10-13
- Market capitalisation$843.7M
- Price to earnings56.5
- EPS (diluted, trailing year)$-1.91
- Volume (last session)2,714,008
Financials of Monte Rosa Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $123.7M | -$38.6M | -$45.9M |
| 2024 | $75.6M | -$72.7M | -$73.0M |
| 2023 | -$135.3M | -$137.1M | |
| 2022 | -$108.5M | -$103.8M | |
| 2021 | -$74.0M | -$70.8M |
Detailed financial statements for Monte Rosa Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Monte Rosa Therapeutics
4 dated milestones of Monte Rosa Therapeutics across 1 years, from founding to its latest funding, stage changes and deals.
- Founded Monte Rosa Therapeutics is founded.
- Funding First funding round of $32.5M.
- Funding Latest funding round, Series C, of $95.0M.
- IPO Lists on the stock exchange (IPO).
Web traffic of Monte Rosa Therapeutics
The website of Monte Rosa Therapeutics (monterosatx.com) receives about 27.7K visits a month and ranks #1,555,357 among all websites worldwide, #2,067 in Biotechnology and Pharmaceuticals.
- Monthly visits27.7K
▲ 54.5% vs previous month
- Unique visitors7.2K
per month
- Global rank#1,555,357
among all websites
- Category rank#2,067
Health · Biotechnology and Pharmaceuticals
- Bounce rate54%
- Pages per visit1.5
- Average visit23 sec
- DevicesDesktop 53% · Mobile 47%
Websites whose visitors overlap most with Monte Rosa Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| swissbiotech.org | 100% | 63.9K | #658,452 | View details | |
pharmanow.live | pharmanow.live | 34% | #1,343,514 | – | |
section-monte-rosa.ch | section-monte-rosa.ch | 32% | #3,585,379 | – |
Top companies in Oncology
3 companies that operate in the same segment as Monte Rosa Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Monte Rosa Therapeutics
Complete news archive for Monte Rosa Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Monte Rosa Therapeutics
Monte Rosa Therapeutics was founded in 2020.
Monte Rosa Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Monte Rosa Therapeutics is a funded company, having raised a total of $223.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $32.5M, raised on May 2020.
Monte Rosa Therapeutics has 134 employees.
Annual revenue of Monte Rosa Therapeutics is $123.67M as on Dec 31, 2025.
Monte Rosa Therapeutics was founded in 2020 in Cambridge, United States, within the biotechnology sector. Small molecule degraders are created to reprogram protein homeostasis pharmacologically. Targeted protein degradation is facilitated through molecular glues that control ubiquitination of disease-causing proteins by E3 ligase complexes. Operations focus on oncology therapeutics, with Thalidomide developed specifically for multiple myeloma treatment.
Monte Rosa Therapeutics offers Molecular Glue Degraders.
Yes, Monte Rosa Therapeutics is publicly traded on NASDAQ under the ticker symbol GLUE.
Monte Rosa Therapeutics has 13 investors. Key investors include Fidelity Investments, BlackRock, RTW Investments, HBM Healthcare Investments, and Avoro Capital Advisors.
Monte Rosa Therapeutics operates through Monte Rosa Therapeutics Ag.